Knockdown of FAM3C inhibits breast cancer tumour growth
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
List view / Grid view
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
The ML algorithm explores how genetic mutations collectively influence a tumour’s reaction to drugs impeding DNA replication.
Using an AI algorithm to predict glioblastoma’s most active kinase, researchers hope for a next-generation precision therapy targeting resistant cancers.
Researchers discover a key metabolic process that cancer cells use to grow in a nutrient deprived environment, which could be a new target.
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.
A new blood panel test reports the tumour fraction and the tumour type of prostate cancer with a high level of accuracy.
Novel self-assembled amino acid-based nanoparticles, loaded with doxorubicin, could evolve cancer treatment.
A new study could result in CTLA-4 inhibitors that promote antitumour responses without causing intestinal diseases, such as colitis.
A novel peptide can suppress MYC by binding directly to it with sub-micro-molar affinity, advancing cancer drug development.
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
Understanding the involvement of Nod1 in the development of blood stem cells could greatly improve blood disorder treatments.
Glioblastomas can resist immunotherapy as perivascular fibroblasts support the creation of an immunosuppressive tumour environment.